Investigational drug · Phase 2
anti-TL1A monoclonal antibody
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ulcerative Colitis (UC), Crohn's Disease (CD).
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "anti-TL1A monoclonal antibody"
First trial start
2025
Aug 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "anti-TL1A monoclonal antibody", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ulcerative Colitis (UC)
- Crohn's Disease (CD)
Approved drugs for the same conditions: Crohn's disease · Ulcerative colitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "anti-TL1A monoclonal antibody" as an intervention, largest first.
- Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's DiseasePivotal-lookingRecruiting
BiocadIndustry
NCT07078994 · 204 participants (planned) · Start Aug 14, 2025 · Primary completion May 2027
Drug: anti-TL1A monoclonal antibody, low dose; anti-TL1A monoclonal antibody, medium dose and 1 more · For: Crohn's Disease (CD)
Sites: Barnaul, Russia; Ufa, Russia; Moscow, Russia · 20 sites in all
- Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative ColitisPivotal-lookingRecruiting
BiocadIndustry
NCT07080034 · 198 participants (planned) · Start Aug 14, 2025 · Primary completion Jan 2027
Drug: anti-TL1A monoclonal antibody, low dose; anti-TL1A monoclonal antibody, medium dose and 1 more · For: Ulcerative Colitis (UC)
Sites: Barnaul, Russia; Ufa, Russia; Rostov-on-Don, Russia · 20 sites in all
- Evaluate Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BCD-261 After Single Subcutaneous Injection in Healthy Chinese VolunteersActive, not recruiting
SPH-BIOCAD (HK) LimitedIndustry
NCT07535775 · 48 participants (planned) · Start May 11, 2026 · Primary completion Oct 10, 2026
Drug: BCD-261 · For: Healthy Adult Participants
Sites: Shanghai, China · 2 sites in all
BiocadIndustry
NCT06715540 · 48 participants (planned) · Start Mar 29, 2024 · Primary completion Feb 2025
Drug: BCD-261, dose 1; BCD-261, dose 2 and 7 more · For: Healthy
Sites: Saint Petersburg, Russia
- A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative ColitisTerminated
Vial Australia Pty LtdIndustry
NCT07029971 · 16 participants · Start Jun 23, 2025 · Primary completion Dec 23, 2025
Drug: BB-TL1A-VIAL-HLE · For: Ulcerative Colitis (UC)
Sites: Sydney, Australia; Warriewood, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Therapeutic Potential of Tulisokibart and Anti-TL1A Therapy in Inflammatory Disorders: Current Insights and Future Directions.
Sia J, Lee B, Oon HH · Clin Rev Allergy Immunol 2026
- Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.
Feagan BG, Sands BE, Siegel CA, et al. · Lancet Gastroenterol Hepatol 2025
- Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
Sands BE, Feagan BG, Peyrin-Biroulet L, et al. · N Engl J Med 2024
- Anti-TL1A monoclonal antibody modulates the dysregulation of Th1/Th17 cells and attenuates granuloma formation in sarcoidosis by inhibiting the PI3K/AKT signaling pathway.
Ma C, Huang J, Zheng Y, et al. · Int Immunopharmacol 2024
- Hydrogen/deuterium exchange mass spectrometry and computational modeling reveal a discontinuous epitope of an antibody/TL1A Interaction.
Huang RY, Krystek SR, Felix N, et al. · MAbs 2018
Also in development for Ulcerative Colitis (UC)
- Hemay005Mufemilast, Phosphodiesterase 4 inhibitorsPhase 34 trials
Ganzhou Hemay Pharmaceutical Co., Ltd · Moderate to Severe Ulcerative Colitis, Ulcerative Colitis (UC), COPD (Chronic Obstructive Pulmonary Disease)
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
- HSK47388Phase 22 trials
Haisco Pharmaceutical Group Co., Ltd. · Plaque Psoriasis, Ulcerative Colitis (UC)
- INT-210Phase 21 trial
Innatus Therapeutics (Shanghai) Co., Ltd. · Ulcerative Colitis (UC)
- MB-001Phase 21 trial
Mage Biologics · Ulcerative Colitis (UC)
- MGT-006Phase 21 trial
Metagen Therapeutics, Inc. · Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
- MT-201Phase 21 trial
Mirador Therapeutics, Inc. · Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
- MT-501Phase 21 trial
Mirador Therapeutics, Inc. · Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.